ON Holding AG vs BIO-TECHNE Corp — how do they compare? ON Holding AG trades at $36.73 (market cap $12.41B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: ON Holding AG and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| ONON | TECH | |
|---|---|---|
Market Cap | $12.41B | $11.16B |
Sector | Technology | Health |
52-Week High | $51.75 | $72.12 |
52-Week Low | $31.88 | $43.31 |
Enterprise Value | $11.73B | $11.24B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
ONON trades at $37.65, up 1.21% today, with a bullish technical trend and strong support at $37. The company shows robust fundamentals with Q1 2026 EPS of $0.47 beating expectations, revenue of $3.01B in 2025, and a net income margin of 8.02%. Analyst sentiment is highly positive, with 76.92% recommending Buy and a consensus price target of $47.33, indicating significant upside potential from current levels.
Outlook remains favorable driven by earnings beats and margin expansion, but risks include high valuation multiples like a P/E of 40.62 and competitive pressures in the athletic apparel sector. The stock's growth trajectory hinges on sustaining innovation and market share gains amid economic uncertainties.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Trailing returns across standard periods
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →